Marengo Therapeutics and Ipsen announced Monday that they have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.

A study published this month in Science discusses data that may support a devious alter ego of T-cells present within colorectal cancer tumors.